Inhibikase Therapeutics, Inc. (IKT) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Inhibikase Therapeutics reported revenue of $0. Net income was -$48.3M, or -$0.49 per diluted share. Operating activities generated -$27.8M of cash, leaving -$27.8M of free cash flow. At fiscal year end, Inhibikase Therapeutics held $181.2M in total assets against $8.3M in total liabilities, including $178.8M of cash and equivalents.
Open the full interactive Inhibikase Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Inhibikase Therapeutics Key Stats
| Share Price | $1.76 |
|---|---|
| Market Cap | $307.2M |
| 52-Week Range | $1.41 – $2.52 |
| Shares Outstanding | 174.6 million (basic, 2026 Q2) |
Inhibikase Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $3.1M | $123,440 | $260,501 | $0 | $0 |
| Cost of Goods Sold | — | — | — | — | $52.0M |
| Gross Profit | — | — | — | — | -$52.0M |
| Operating Income | -$14.8M | -$18.1M | -$20.1M | -$28.6M | -$52.0M |
| Pre-Tax Income | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48,259 |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M |
| Diluted EPS | -$4.86 | -$4.32 | -$3.57 | -$1.16 | -$0.49 |
Inhibikase Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$11.9M | -$12.7M | -$16.4M | -$19.6M |
| Diluted EPS | -$0.13 | -$0.13 | -$0.10 | -$0.11 |
Inhibikase Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | — | $7.2M | $9.2M | $56.5M | $178.8M |
| Current Assets | — | $24.4M | $14.2M | $98.5M | $180.1M |
| Total Assets | $42.5M | $24.9M | $14.5M | $98.6M | $181.2M |
| Current Liabilities | $4.1M | $3.7M | $3.4M | $3.7M | $8.3M |
| Total Long-Term Debt | $248,911 | $145,836 | $381,784 | $110,517 | — |
| Total Liabilities | $4.1M | $3.9M | $3.5M | $3.7M | $8.3M |
| Shareholders' Equity | $38.4M | $21.0M | $11.0M | $94.9M | $172.9M |
Inhibikase Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$14.3M | -$17.4M | -$18.1M | -$19.1M | -$27.8M |
| Cash From Investing | — | -$16.0M | $11.7M | -$37.0M | $2.1M |
| Cash From Financing | $41.1M | -$204,769 | $8.4M | $103.5M | $108.5M |
| Free Cash Flow | — | -$17.6M | -$18.1M | -$19.1M | -$27.8M |
Figures from Inhibikase Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Inhibikase Therapeutics financials page for every line item.
Inhibikase Therapeutics Company Profile
| Ticker | IKT |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Wilmington, Delaware |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001750149 |
Frequently Asked Questions
What was Inhibikase Therapeutics' revenue in fiscal 2025?
Inhibikase Therapeutics (IKT) reported revenue of $0 for fiscal 2025.
What is Inhibikase Therapeutics' annual revenue history?
Inhibikase Therapeutics' annual revenue by fiscal year: 2021: $3.1M; 2022: $123,440; 2023: $260,501; 2024: $0; 2025: $0.
What was Inhibikase Therapeutics' net income in fiscal 2025?
Inhibikase Therapeutics reported net income of -$48.3M for fiscal 2025.
What was Inhibikase Therapeutics' earnings per share (EPS) in fiscal 2025?
Inhibikase Therapeutics' diluted EPS was -$0.49 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Inhibikase Therapeutics generate in fiscal 2025?
Inhibikase Therapeutics generated -$27.8M of free cash flow in fiscal 2025.
What was Inhibikase Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Inhibikase Therapeutics reported revenue of $0.
How many shares of Inhibikase Therapeutics are outstanding?
Inhibikase Therapeutics reported a weighted average of 174.6 million basic shares outstanding in 2026 Q2.
What is Inhibikase Therapeutics' market cap?
Based on its latest closing price, Inhibikase Therapeutics (IKT) has a market capitalization of about $307.2M.
When does Inhibikase Therapeutics' fiscal year end?
Inhibikase Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Inhibikase Therapeutics headquartered?
Inhibikase Therapeutics lists its business address in Wilmington, Delaware in its SEC filings.
Inhibikase Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →